FEATURED EDITORIAL
By continuously analyzing spent media, researchers can estimate reaction rates at regular time points, providing a granular view of cell metabolism.
- The Supreme Court Rules On Trump Tariffs. Why Shout "Hooray!"?
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
- The Firefighting Era Of Clinical Supply Chain Is Over. Here's What Replaces It
- The Hidden Engineering Behind Successful Upstream Bioprocessing
- A Practical Look At Modern Downstream Processing For Biologics
- From Biology Grad To Manufacturing Guru
- Process Engineering's Key Role In Sterile Injectable Facility Design
GUEST COLUMNISTS
-
The Firefighting Era Of Clinical Supply Chain Is Over. Here's What Replaces It
Clinical trial supply chains are evolving: digital twins, on-demand kits, and sustainable logistics replace reactive firefighting with precision, speed, and resilience.
-
The Hidden Engineering Behind Successful Upstream Bioprocessing
In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
-
A Practical Look At Modern Downstream Processing For Biologics
Part 2 in a series about current bioprocessing practices explores the latest in separation, purification, sterile filtration and aseptic filling.
-
Process Engineering's Key Role In Sterile Injectable Facility Design
Quality requirements for parenteral drugs complicate facility design like few other regulated products. If you're developing injectables, be aware of these key issues.
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
-
MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.
-
A Novel In Vitro Glycosylation Approach For Difficult PTMs
Post-translational modifications of membrane proteins have been historically challenging. Research shows how an in vitro approach brings stability and predictability.
-
Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
Risk and fitness for use of interchangeable single-use parts were key themes at the conference. The event exposed communication gaps between suppliers and end-users.
PHARMA OUTSOURCING WHITE PAPERS
-
5 Steps To Design A Microbiological Performance Qualification For Facilities Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
-
Why An Integrated Approach Ensures Smooth Entry Into The European Market
Simplify your EU launch and boost returns. Learn how to manage regulatory hurdles, access a huge patient population, and gain end-to-end commercial support.
-
A Patented Process For Intermediates Useful For Upadacitinib
Discover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.
-
Reducing Costs & Risks: A Pharma Guide To FTZ Subzones For U.S. Drug Manufacturing
Utilized wisely, FTZs and subzones can be tools for cost savings and can enable pharma companies to leverage the benefits of American manufacturing.
-
Sustainability In Small Molecule API Manufacturing
Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing.
-
What FDA CRLs Reveal About E&L
FDA feedback shows E&L gaps still delay approvals. This preview flags common issues — from unknown compounds to weak tox data — and offers ways to strengthen E&L approaches and cut regulatory risk.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Analytical Method Saves Dual-API Injectable Project From Stalling
- Optimizing Performance For De-Risked Lentiviral Vector Production
- CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics
- Handling Demanding Active Ingredients Safely And Efficiently
- Accelerating A Complex Molecule From CLD To cGMP In 12 Months